News

The Dose Podcast: Ep 1 "TB and the AMR Crisis"

The Stop TB Partnership's Working Group on New Drugs presents a new podcast series entitled "The Dose". In this series, the WGND will bring together drug developers, researchers in the TB R&D field, TB patients, global health experts, and donors to discuss, prioritize, and develop strategies to help meet the most pressing needs faced by the TB drug R&D community.

Episode 1 "TB and the AMR Crisis"

Episode 1 will focus on TB and antimicrobial resistance (AMR). Today, AMR is one of the defining health issues of our time. Drug resistant tuberculosis is the cornerstone of the global AMR challenge, which accounts for a quarter of AMR fatalities per year. This podcast will highlight the opportunities, and challenges to advancing action on AMR and tuberculosis.

Moderator: Shobha Shukla, Citizen News Service

Speaker: Mario Raviglione, University of Milan (Previously Global TB Programme, WHO) 

Speaker: Manica Balasegaram, Global Antibiotic Research and Develpment Partnership (GARDP)

 

Listen on Soundcloud: https://soundcloud.com/user-87209407/the-dose-podcast-july-2018 

More News
21 Mar 2019
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
12 Mar 2019
On March 8th, TB Alliance announced its novel compound, Pretomanid, is currently being reviewed by the FDA for use against Tuberculosis. TB Alliance's press release can be found below: NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug...
29 Nov 2018
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...